Amphastar Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Amphastar Pharmaceuticals has a total shareholder equity of $713.3M and total debt of $586.6M, which brings its debt-to-equity ratio to 82.2%. Its total assets and total liabilities are $1.5B and $778.2M respectively. Amphastar Pharmaceuticals's EBIT is $232.6M making its interest coverage ratio 10.1. It has cash and short-term investments of $217.8M.
Key information
82.2%
Debt to equity ratio
US$586.58m
Debt
| Interest coverage ratio | 10.1x |
| Cash | US$217.78m |
| Equity | US$713.35m |
| Total liabilities | US$778.18m |
| Total assets | US$1.49b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 29A's short term assets ($482.6M) exceed its short term liabilities ($137.0M).
Long Term Liabilities: 29A's short term assets ($482.6M) do not cover its long term liabilities ($641.2M).
Debt to Equity History and Analysis
Debt Level: 29A's net debt to equity ratio (51.7%) is considered high.
Reducing Debt: 29A's debt to equity ratio has increased from 10.6% to 82.2% over the past 5 years.
Debt Coverage: 29A's debt is well covered by operating cash flow (36.2%).
Interest Coverage: 29A's interest payments on its debt are well covered by EBIT (10.1x coverage).